Medical/Pharmaceuticals

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...

2022-01-11 16:30 4586

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...

2022-01-11 15:15 3319

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...

2022-01-11 14:29 1879

MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week

DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...

2022-01-11 14:00 2754

Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy , the US-based enterprise analytics platform, supportedPfizer, an American multinational pharmaceutical and biotechnology corporation, to usher in a future of sustainable data culture. With the help of solut...

2022-01-11 09:30 3311

Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod

* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...

2022-01-11 09:00 3254

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...

2022-01-11 08:30 4487

Dr. Ivan Puah Highlights The Significant Impact Of Covid That Changes Our Priority In Life

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- The current pandemic has raised more awareness of the importance of health and better care of oneself. Dr.Ivan Puah, Medical Director at Amaris B. Clinic shares how people's lifestyles and priorities have changed since Covid-19 started. 01. Losing we...

2022-01-11 06:44 2674

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...

2022-01-11 05:30 5173

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China andSHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage ...

2022-01-11 05:30 3887

Trajan Group acquires Neoteryx LLC

MELBOURNE, Australia, Jan. 10, 2022 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Neoteryx, LLC (Neoteryx), a global leader in blood microsampling devices based inTorrance, California,...

2022-01-11 00:00 3510

The new symptoms of the COVID period that CDAHK doctors have uncovered

HONG KONG, Jan. 10, 2022 /PRNewswire/ -- As the COVID-19 Omicron variety continues to spread, chiropractors see a spike in neck pathology from work-from-home, remote learning during pandemic. For 30 years before the COVID-19 pandemic, the majority of chiropractic patients were suffering from bac...

2022-01-10 23:52 2694

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced thatthe United States Food and Drug Administration (FDA)...

2022-01-10 21:50 4273

New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation

PLYMOUTH MEETING, Pa., Jan. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a donor stem cell or bone marrow (a.k.a. hematopo...

2022-01-10 21:37 2295

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD (Merck & Co., Inc.,  Kenilworth, N...

2022-01-10 21:35 5354

Clinical study on Bactiguard's endotracheal tube now published - shows significant reduction of ventilator-associated pneumonia

STOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube. It was presented for th...

2022-01-10 20:57 2374

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...

2022-01-10 16:00 3372

Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. AS...

2022-01-10 08:30 4490

SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE

SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...

2022-01-07 23:00 3845

Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay

FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ -- Vela Diagnostics announced that itsSentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) startingJanuary 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare...

2022-01-07 22:00 3016
1 ... 603604605606607608609 ... 644

Week's Top Stories